Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech such as Celldex Therapeutics means untangling pages of trial data, FDA risk factors, and stock-based compensation tables. If you have ever opened Celldex’s latest 10-K only to hunt for cash-runway disclosures or barzolvolimab trial timelines, you know the challenge.
Stock Titan solves it. Our AI reads every Celldex Therapeutics quarterly earnings report 10-Q filing, annual report 10-K, and 8-K material event the moment it hits EDGAR, then translates the biotech jargon into plain English summaries, key metrics, and trend charts you can grasp in minutes. Want to monitor Celldex Therapeutics insider trading Form 4 transactions? Real-time alerts surface executive stock moves so you can gauge insider conviction without scanning multiple PDFs.
- 10-K & 10-Q—cash burn, R&D spend by program, pivotal trial milestones, all explained simply.
- Form 4—insider buys or sells, including Celldex Therapeutics executive stock transactions Form 4, delivered as they post.
- 8-K—material disclosures like breakthrough-therapy designations or financing deals, with context on why they matter.
- Proxy statements—clear breakdowns of Celldex Therapeutics proxy statement executive compensation for benchmarking management incentives.
Whether you are asking “How do I read Celldex Therapeutics’ 10-K?” or comparing Form 4 patterns ahead of trial data, Stock Titan’s AI-powered analysis keeps you ahead. Save hours, spot risks early, and make better calls on this mast-cell biology leader—without wading through every page.
Celldex Therapeutics senior executive reports stock option exercises. A company officer serving as Senior Vice President and Chief Business Officer filed a Form 4 covering two option exercises in Celldex Therapeutics, Inc. common stock on 12/15/2025. The reporting person acquired 8,333 shares at an exercise price of $9.0165 per share and 11,000 shares at an exercise price of $2.78 per share through the exercise of incentive stock options.
Following these transactions, the officer beneficially owns 20,097 shares of Celldex common stock directly, which includes 764 shares acquired under the company’s 2004 Employee Stock Purchase Plan. After the exercises, one option grant for 8,333 shares expiring on 06/13/2028 remains partially outstanding with 5,000 derivative securities beneficially owned, while a second option grant for 11,000 shares expiring on 06/19/2029 has been fully exercised.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.
Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.
Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of
The filing states 25% of the award vests on
Celldex Therapeutics (CLDX) filed a Form 3, the initial statement of beneficial ownership for a company insider. The reporting person is Teri Lawver, who serves as SVP & Chief Commercial Officer. The filing states that no securities are beneficially owned by the reporting person.
The date of event is 11/10/2025, and the form was filed on an individual basis. The document was signed by /s/ Sam Martin, attorney-in-fact for Teri Lawver on 11/12/2025.
Celldex Therapeutics (CLDX) filed its Q3 2025 10-Q, reporting no revenue for the quarter and higher operating spend as clinical programs advanced. For the three months ended September 30, 2025, operating expenses were $73.6 million and the company recorded a net loss of $67.0 million (vs. $42.1 million a year ago). For the nine months, operating expenses were $201.6 million with a net loss of $177.4 million.
Liquidity remains strong: as of September 30, 2025, cash, cash equivalents and marketable securities totaled $583.2 million. Net cash used in operating activities was $147.0 million for the nine months. Management states these resources are expected to fund operations for at least the next twelve months from issuance. R&D spend is led by the barzolvolimab (anti‑KIT) program, which accounted for $133.97 million of R&D in the nine-month period; CDX‑622 and other programs accounted for the balance. An at‑the‑market facility with $300.0 million registered capacity remained unsold at quarter end. Common shares outstanding were 66,446,846 at September 30, 2025.
Celldex Therapeutics (CLDX) reported that it furnished a press release announcing its third‑quarter 2025 financial results. The company disclosed this under Item 2.02 and attached the full press release as Exhibit 99.1, which is incorporated by reference.
The company stated the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
Celldex Therapeutics insider sale disclosure: Freddy A. Jimenez, SVP & General Counsel and officer of Celldex Therapeutics, reported two open-market dispositions of common stock on 08/13/2025. He sold 341 shares at $23.9515 and 430 shares at $25.415. After these transactions he beneficially owned 34,962 shares. The filing notes 269 of the reported shares were acquired under the company’s 2004 Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
This Schedule 13G/A reports that Eventide Asset Management, LLC and two individuals, Finny Kuruvilla, M.D., Ph.D. and Robin C. John, each are associated with an aggregate beneficial ownership of 1,356,186 shares of Celldex Therapeutics common stock, representing 2.0% of the class. The filing cites the date of event requiring filing as 06/30/2025 and contains signatures dated 08/14/2025.
Eventide is reported with sole voting and sole dispositive power over 1,356,186 shares, while Kuruvilla and John are reported with shared voting and shared dispositive power over the same 1,356,186 shares. Item 5 explicitly states this is an ownership of 5 percent or less of a class.
The filing identifies Eventide as organized in Delaware and lists the filers' address as One International Place, Suite 4210, Boston, Massachusetts. The exhibit includes a joint filing agreement executed August 14, 2025, and Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Celldex Therapeutics (CLDX)?
What is the market cap of Celldex Therapeutics (CLDX)?
